Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.

Brüggemann M, Kotrová M, Knecht H, Bartram J, Boudjogrha M, Bystry V, Fazio G, Froňková E, Giraud M, Grioni A, Hancock J, Herrmann D, Jiménez C, Krejci A, Moppett J, Reigl T, Salson M, Scheijen B, Schwarz M, Songia S, Svaton M, van Dongen JJM, Villarese P, Wakeman S, Wright G, Cazzaniga G, Davi F, García-Sanz R, Gonzalez D, Groenen PJTA, Hummel M, Macintyre EA, Stamatopoulos K, Pott C, Trka J, Darzentas N, Langerak AW; EuroClonality-NGS working group.

Leukemia. 2019 Jun 26. doi: 10.1038/s41375-019-0496-7. [Epub ahead of print]

PMID:
31243313
2.

Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS.

Knecht H, Reigl T, Kotrová M, Appelt F, Stewart P, Bystry V, Krejci A, Grioni A, Pal K, Stranska K, Plevova K, Rijntjes J, Songia S, Svatoň M, Froňková E, Bartram J, Scheijen B, Herrmann D, García-Sanz R, Hancock J, Moppett J, van Dongen JJM, Cazzaniga G, Davi F, Groenen PJTA, Hummel M, Macintyre EA, Stamatopoulos K, Trka J, Langerak AW, Gonzalez D, Pott C, Brüggemann M, Darzentas N; EuroClonality-NGS Working Group.

Leukemia. 2019 Jun 21. doi: 10.1038/s41375-019-0499-4. [Epub ahead of print]

PMID:
31227779
3.

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.

Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P.

Clin Cancer Res. 2019 Jul 15;25(14):4455-4465. doi: 10.1158/1078-0432.CCR-18-3275. Epub 2019 Apr 19.

PMID:
31004002
4.

CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID.

Kralickova P, Milota T, Litzman J, Malkusova I, Jilek D, Petanova J, Vydlakova J, Zimulova A, Fronkova E, Svaton M, Kanderova V, Bloomfield M, Parackova Z, Klocperk A, Haviger J, Kalina T, Sediva A.

Front Immunol. 2019 Jan 22;9:3135. doi: 10.3389/fimmu.2018.03135. eCollection 2018.

5.

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer.

Svaton M, Zemanova M, Skrickova J, Jakubikova L, Kolek V, Kultan J, Koubkova L, Bejckova A, Salajka F, Hrnciarik M, Melichar B, Vrana D, Konecny M, Chloupkova R, Pesek M.

Anticancer Res. 2018 Dec;38(12):6771-6782. doi: 10.21873/anticanres.13048.

PMID:
30504389
6.

Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.

Bloomfield M, Kanderová V, Paračková Z, Vrabcová P, Svatoň M, Froňková E, Fejtková M, Zachová R, Rataj M, Zentsová I, Milota T, Klocperk A, Kalina T, Šedivá A.

J Clin Immunol. 2018 Jul;38(5):589-601. doi: 10.1007/s10875-018-0519-6. Epub 2018 Jun 22.

PMID:
29934865
7.

[Patient with Three EGFR Mutations - Gradual Development of Resistance to Previous Targeted Treatment].

Svatoň M, Pešek M, Baxa J, Mukenšnabl P, Benešová L, Minárik M.

Klin Onkol. Winter 2017;31(1):53-58. doi: 10.14735/amko201853. Czech.

PMID:
29488779
8.

Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy.

Kulda V, Svaton M, Mukensnabl P, Hrda K, Dvorak P, Houdek Z, Houfkova K, Vrzakova R, Babuska V, Pesek M, Pesta M.

Oncol Lett. 2018 Jan;15(1):592-599. doi: 10.3892/ol.2017.7337. Epub 2017 Nov 2.

9.

Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.

Kulda V, Hrda K, Houdek Z, Dobra JK, Vrzakova R, Svaton M, Safranek J, Dolezal J, Babuska V, Pesek M, Topolcan O, Pesta M.

Anticancer Res. 2017 Dec;37(12):6953-6958.

PMID:
29187479
10.

Short Stature in a Boy with Multiple Early-Onset Autoimmune Conditions due to a STAT3 Activating Mutation: Could Intracellular Growth Hormone Signalling Be Compromised?
.

Sediva H, Dusatkova P, Kanderova V, Obermannova B, Kayserova J, Sramkova L, Zemkova D, Elblova L, Svaton M, Zachova R, Kolouskova S, Fronkova E, Sumnik Z, Sediva A, Lebl J, Pruhova S.

Horm Res Paediatr. 2017;88(2):160-166. doi: 10.1159/000456544. Epub 2017 Mar 2.

PMID:
28253502
11.

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Fiala O, Pesek M, Skrickova J, Kolek V, Salajka F, Tomiskova M, Satankova M, Kultan J, Kuliskova J, Svaton M, Hrnciarik M, Hejduk K, Chloupkova R, Topolcan O, Hornychova H, Nova M, Ryska A, Finek J.

Tumour Biol. 2017 Feb;39(2):1010428317691186. doi: 10.1177/1010428317691186.

PMID:
28218046
12.

Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.

Fiala O, Pesek M, Finek J, Topolcan O, Racek J, Svaton M, Kucera R, Minarik M, Benesova L, Bortlicek Z, Chloupkova R, Poprach A, Buchler T.

Anticancer Res. 2016 May;36(5):2459-65.

PMID:
27127158
13.

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.

Svaton M, Fiala O, Pesek M, Bortlicek Z, Minarik M, Benesova L, Topolcan O.

Anticancer Res. 2016 Mar;36(3):1077-82.

PMID:
26977001
14.

[Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib].

Svaton M, Pešek M.

Klin Onkol. 2016;29(1):63-5. Czech.

PMID:
26879065
15.

Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.

Fiala O, Pesek M, Finek J, Svaton M, Sorejs O, Bortlicek Z, Kucera R, Topolcan O.

Anticancer Res. 2016 Jan;36(1):461-6.

PMID:
26722082
16.

Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.

Fiala O, Pesek M, Finek J, Minarik M, Benesova L, Sorejs O, Svaton M, Bortlicek Z, Kucera R, Topolcan O.

Anticancer Res. 2016 Jan;36(1):455-60.

PMID:
26722081
17.

Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene.

Fiala O, Pesek M, Finek J, Svaton M, Minarik M, Benesova L, Bortlicek Z, Kucera R, Topolcan O.

Anticancer Res. 2016 Jan;36(1):447-53.

PMID:
26722080
18.

Current two EGFR mutations in lung adenocarcinoma -  case report.

Svaton M, Pesek M, Chudacek Z, Vosmiková H.

Klin Onkol. 2015;28(2):134-7.

PMID:
25882025
19.

Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib.

Svaton M, Fiala O, Pesek M, Bruha F, Mukensnabl P, Racek J, Minarik M, Bortlicek Z.

Anticancer Res. 2014 Dec;34(12):7461-5.

PMID:
25503188
20.

The TREC/KREC assay for the diagnosis and monitoring of patients with DiGeorge syndrome.

Froňková E, Klocperk A, Svatoň M, Nováková M, Kotrová M, Kayserová J, Kalina T, Keslová P, Votava F, Vinohradská H, Freiberger T, Mejstříková E, Trka J, Sedivá A.

PLoS One. 2014 Dec 8;9(12):e114514. doi: 10.1371/journal.pone.0114514. eCollection 2014.

Supplemental Content

Loading ...
Support Center